Search Results

Your search matched 9 results


EFPIA W.A.I.T. | Blog

The European Federation of Pharmaceutical Industries and Association (EFPIA) Waiting to Access Innovative Therapies (W.A.I.T.)


The U.S. | Blog

Democrats have revealed that the next major legislative package—colloquially known as the infrastructure package—will likely include provisions to lower prescription drug prices.


Biden Supports Waiving IP Protections for COVID-19 Vaccines. | Blog

As you may have read, the Biden administration announced last week that it will support a proposal to temporarily waive certain intellectual property (IP) protections for COVID-19 vaccines and therapies.


Multiple inflection points are colliding that will force action on drug pricing in the U.S. | Blog

An update on the latest developments in Washington critical to Pharma leaders.


Post–Biogen’s Aduhelm Approval, Prepare for Increased Scrutiny | Blog

Within a few days of the Aduhelm approval, the conversation quickly shifted from the first treatment for Alzheimer’s disease to the exorbitant cost ($56,000 annually) and whether the budgetary impact on society of the drug’s broad label is worth the therapeutic outcomes.


POV: Shifting winds - policy changes threaten decades of progress in orphan medicines | Blog

The World Orphan Drug Congress Europe (WODC) looked back on the remarkable achievements of the last 20 years of the General Pharmaceutical Legislation (GPL) in Europe.


Biden Executive Order Makes Communicating Your Value Proposition More Important than Ever | Blog

This month, we’ve seen a flurry of activity that confirms Washington will be focused on drug pricing this summer, and it’s coming from all directions: Congress, the Biden Administration, and Courts.


A New Drug Price Deal Signals Significant Policy Shift | Blog

This month policies aimed at lowering drug prices are back on the table.


What Biogen’s Alzheimer’s Drug Approval Means for Life Sciences Companies | Blog

In a highly anticipated decision, the Food and Drug Administration (FDA) last week cleared Alzheimer’s disease drug aducanumab on an accelerated, conditional approval program.